EA201200865A1 - Терапевтическое применение конъюгатов белка с полимером - Google Patents

Терапевтическое применение конъюгатов белка с полимером

Info

Publication number
EA201200865A1
EA201200865A1 EA201200865A EA201200865A EA201200865A1 EA 201200865 A1 EA201200865 A1 EA 201200865A1 EA 201200865 A EA201200865 A EA 201200865A EA 201200865 A EA201200865 A EA 201200865A EA 201200865 A1 EA201200865 A1 EA 201200865A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
polymer
conjugats
therapeutic application
idiopathic
Prior art date
Application number
EA201200865A
Other languages
English (en)
Other versions
EA022354B1 (ru
EA022354B9 (ru
Inventor
Ко-Чун Линь
Рудольф Др. Видманн
Original Assignee
Фармаэссентия Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармаэссентия Корпорейшн filed Critical Фармаэссентия Корпорейшн
Publication of EA201200865A1 publication Critical patent/EA201200865A1/ru
Publication of EA022354B1 publication Critical patent/EA022354B1/ru
Publication of EA022354B9 publication Critical patent/EA022354B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Abstract

Это изобретение имеет отношение к применению конъюгатов белка с полимером, описанных в подробном описании, для лечения различных болезней, включая идиопатический миелофиброз, истинную полицитемию и идиопатическую тромбоцитемию.
EA201200865A 2009-12-10 2010-12-09 Терапевтическое применение конъюгатов интерферон-пэг EA022354B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28541109P 2009-12-10 2009-12-10
PCT/US2010/059714 WO2011072138A2 (en) 2009-12-10 2010-12-09 Therapeutic use of protein-polymer conjugates

Publications (3)

Publication Number Publication Date
EA201200865A1 true EA201200865A1 (ru) 2012-11-30
EA022354B1 EA022354B1 (ru) 2015-12-30
EA022354B9 EA022354B9 (ru) 2016-02-29

Family

ID=44146181

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200865A EA022354B9 (ru) 2009-12-10 2010-12-09 Терапевтическое применение конъюгатов интерферон-пэг

Country Status (32)

Country Link
US (1) US8617532B2 (ru)
EP (1) EP2509593B1 (ru)
JP (1) JP5547816B2 (ru)
KR (1) KR101782084B1 (ru)
CN (1) CN102724980B (ru)
AR (1) AR079369A1 (ru)
AU (1) AU2010328067B2 (ru)
BR (1) BR112012014017B1 (ru)
CA (1) CA2782624C (ru)
CL (1) CL2012001503A1 (ru)
CY (1) CY1122901T1 (ru)
DK (1) DK2509593T3 (ru)
EA (1) EA022354B9 (ru)
ES (1) ES2786025T3 (ru)
HK (1) HK1176015A1 (ru)
HR (1) HRP20200678T1 (ru)
HU (1) HUE049051T2 (ru)
IL (1) IL220249A0 (ru)
LT (1) LT2509593T (ru)
MA (1) MA33913B1 (ru)
MX (1) MX337705B (ru)
MY (1) MY169961A (ru)
NZ (1) NZ600528A (ru)
PL (1) PL2509593T3 (ru)
PT (1) PT2509593T (ru)
RS (1) RS60336B1 (ru)
SG (1) SG181084A1 (ru)
SI (1) SI2509593T1 (ru)
TN (1) TN2012000256A1 (ru)
UA (1) UA109646C2 (ru)
WO (1) WO2011072138A2 (ru)
ZA (1) ZA201205056B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3215193T3 (pl) * 2014-11-06 2024-03-18 Pharmaessentia Corporation Reżim podawania pegylowanego interferonu

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20074024B (en) * 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method

Also Published As

Publication number Publication date
SI2509593T1 (sl) 2020-07-31
PL2509593T3 (pl) 2020-08-24
LT2509593T (lt) 2020-05-25
AR079369A1 (es) 2012-01-18
NZ600528A (en) 2014-01-31
PT2509593T (pt) 2020-04-21
JP5547816B2 (ja) 2014-07-16
RS60336B1 (sr) 2020-07-31
ES2786025T3 (es) 2020-10-08
BR112012014017A2 (pt) 2016-04-12
KR20120110105A (ko) 2012-10-09
MX2012006132A (es) 2012-06-19
WO2011072138A9 (en) 2011-10-06
WO2011072138A2 (en) 2011-06-16
EP2509593B1 (en) 2020-02-12
DK2509593T3 (da) 2020-05-11
MY169961A (en) 2019-06-19
UA109646C2 (uk) 2015-09-25
CA2782624C (en) 2016-11-01
JP2013513611A (ja) 2013-04-22
CL2012001503A1 (es) 2012-11-09
AU2010328067B2 (en) 2014-10-02
BR112012014017B1 (pt) 2021-10-26
EA022354B1 (ru) 2015-12-30
TN2012000256A1 (en) 2013-12-12
HRP20200678T1 (hr) 2020-10-02
EP2509593A4 (en) 2016-01-13
EP2509593A2 (en) 2012-10-17
SG181084A1 (en) 2012-07-30
CA2782624A1 (en) 2011-06-16
AU2010328067A1 (en) 2012-07-05
ZA201205056B (en) 2013-03-27
MA33913B1 (fr) 2013-01-02
MX337705B (es) 2016-03-15
HUE049051T2 (hu) 2020-09-28
HK1176015A1 (en) 2013-07-19
CN102724980A (zh) 2012-10-10
KR101782084B1 (ko) 2017-09-26
US8617532B2 (en) 2013-12-31
EA022354B9 (ru) 2016-02-29
US20110262380A1 (en) 2011-10-27
CN102724980B (zh) 2014-10-15
IL220249A0 (en) 2012-07-31
CY1122901T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
CY1123404T1 (el) Αντι-girt αντισωματα
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201500314A1 (ru) Лекарственные формы энзалутамида
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
EA201491550A1 (ru) Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях
EA201400579A1 (ru) Антитела к il-36r
CL2012000238A1 (es) Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
CL2014002557A1 (es) Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
EA201391440A1 (ru) Производные пиразолопиримидина
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
UY33833A (es) Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
EA201270315A1 (ru) Новые формы полициклического соединения

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent